Bing

SEARCH HISTORY

BioMarin Pharmaceutical (BMRN) agreed to purchase Prosensa (RNA) for up to $850 million, in an acquisition Leerink’s Joseph P. Schwartz and Paul Matteis call “courageous.” They explain why: While somewhat risky ahead of a potential drisapersen ...
Barron's · 11/24/2014
* = Where indicated, some values are estimates. 1 = Potential proceeds estimated by the filer. 2 = Estimated based on the average of multiple prices reported. 3 = Multiple dates reported. Most recent date shown. Currency in USD.
Yahoo Finance · 1/22/2000
If you want to understand why I’m such a big proponent of biotech-related investments, just look at a stunning report released earlier in the quarter by the IMS Institute for Healthcare Informatics, a unit of IMS Holdings Inc. (NYSE: IMS). The study ...
Money Morning · 2/25/2015
More from Bing News
In a move that could help the Swiss drug giant diversify its products, Roche is reportedly cobbling together up to $15 billion in financing to make a play for U.S. rare disease treatment maker BioMarin Pharmaceutical (BMRN). A possible combination would ...
Fox Business · ByMatt Egan · 9/19/2013
BioMarin Pharmaceutical Inc:Announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for drisapersen for the treatment of Duchenne Muscular Dystrophy amenable to exon 51 skipping.Validation of the …
Reuters · 6/27/2015
Which biopharma stocks should investors have their eyes on for 2015? J.P. Morgan has a few ideas. With JPM analysts predicting the sector can take its hot streak into 2015, they've ID'd companies ranging from tiny BioMarin to whopper Bristol-Myers …
FiercePharma · 12/23/2014
With the FDA decision, Retrophin exercised its option to buy the developer of that drug, Asklepion Pharmaceuticals, of Baltimore, MD—and all of the rights to the drug—for $27 million in cash and 661,278 shares of Retrophin stock. Asklepion’s backers ...
Xconomy · 3/18/2015
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At Customers Bancorp (NYSE:CUBI), a filing with the SEC ...
Market News Video · 6/3/2015
U.S. News evaluated 36 Health/Biotechnology Funds ETFs and 17 make our Best Fit list. Our list highlights the best passively managed funds for long-term investors. Rankings are assigned based on comparisons with Best Fit funds in this category.
USNews · 2/24/2015
Karen Andersen: I'm Karen Andersen, senior biotech analyst at Morningstar. With me today to discuss the M&A environment is biotech analyst Lauren Migliore. Thanks for joining me, Lauren. Lauren Migliore: Good to be here, Karen. Andersen: So, just to …
Morning Star · 5/4/2012